Progyny (NASDAQ:PGNY) is a leading provider of women's health and family-building benefits. The company currently boasts a market capitalization of approximately $1.82 billion. This market capitalization reflects the total market value of its outstanding shares. Over the past year, Progyny's stock price has fluctuated, ranging from a low of $16.10 to a high of $28.75.
On May 15, 2026, a notable development occurred as an analyst from Barclays increased their price target for Progyny to $27.00, an uplift from a previous target of $23.00. At the time of this update, the stock was trading at $23.25 per share. This revised analyst target signals potential for further stock price appreciation from its current level.
This positive analyst update follows a robust financial report for the first quarter of 2026. Progyny announced record revenue of $328.50 million. Furthermore, the company reported earnings per share (EPS) of $0.50. As highlighted by Zacks, this EPS figure surpassed the expected estimate of $0.44 per share and last year's $0.48 per share, demonstrating strong earnings performance.
CEO Pete Anevski attributed these strong results to "healthy member engagement" and high utilization of Progyny's services. First-quarter revenue growth stood at 1.4% compared to the same period last year. The company has consistently exceeded both revenue and earnings estimates for four consecutive quarters, showcasing reliable financial consistency.
As reported by GlobeNewswire, Progyny has also actively enhanced shareholder value. The company executed a share repurchase program, buying back 8.80 million of its own shares since November of the previous year. A share repurchase effectively reduces the number of outstanding shares, which can lead to an increase in the value of the remaining shares for investors.
